NEW YORK, June 10, 2016 /PRNewswire/ -- KCSA Strategic
Communications, a leading provider of integrated communications
solutions announced its participation in the opening bell ringing
ceremony at the Nasdaq MarketSite for its client, Sensus
Healthcare, Inc. (NASDAQ: SRTSU), a medical device company
specializing in the treatment of non-melanoma skin cancers and
other skin conditions, such as keloids. With important employees,
partners and families on hand, Sensus Healthcare Chief Executive
Officer, Joseph Sardano, officially
opened the trading day on Nasdaq. This ceremony comes on the heels
of the successful Initial Public Offering (IPO) of Sensus
Healthcare on Thursday, June 2,
2016.
"The excitement we have when we are able to successfully advise
one of our clients through the listing process on a major U.S.
exchange such as Nasdaq is extremely gratifying," commented
Jeffrey Goldberger, Managing
Partner, KCSA Strategic Communications. "For Sensus Healthcare, its
IPO is the culmination of years of hard work and success. Having
worked closely with management over the past few months to prepare
for this moment is what we live for as investor relations
consultants. We congratulate Joe
Sardano and his team and look forward to working closely
with the team to execute an investor relations program based on
best practices."
"Today's listing on Nasdaq is a significant milestone for Sensus
Healthcare. With decades of experience in the medical device
industry, we launched Sensus with a simple goal – to provide
medical professionals and their patients access to non-invasive
options to treat non-melanoma skin cancer and keloids," noted
Joseph Sardano, Chief Executive
Officer of Sensus Healthcare. "I am extremely proud of the entire
Sensus team and wish to express my sincere gratitude for their
tireless and continued support."
About KCSA Strategic Communications
KCSA is a fully integrated communications agency specializing in
public relations, investor relations and marketing with expertise
in healthcare, technology and financial / professional services.
Since 1969, the firm has demonstrated strategic thinking and
program execution that drives results for its clients in the
ever-changing communications and digital landscape. The firm's
clients are its best references. For more information, please visit
www.kcsa.com.
About Sensus
Sensus Healthcare, Inc. is a medical device company that is
committed to enabling non-invasive and cost-effective treatment of
non-melanoma skin cancers and keloids. Sensus uses a proprietary
low energy x-ray radiation technology known as superficial
radiation therapy (SRT), which is a result of over a decade of
dedicated research and development activities. Sensus has
successfully incorporated the SRT therapy into its portfolio of
treatment devices, the SRT-100™ and SRT-100 Vision™. To date, the
SRT technology has been used to effectively and safely treat
oncological and non-oncological skin conditions in thousands of
patients. For more information, visit
http://www.sensushealthcare.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/kcsa-strategic-communications-advises-sensus-healthcare-on-successful-ipo-300282942.html
SOURCE KCSA Worldwide